These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17451562)

  • 1. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
    Raison CL; Woolwine BJ; Demetrashvili MF; Borisov AS; Weinreib R; Staab JP; Zajecka JM; Bruno CJ; Henderson MA; Reinus JF; Evans DL; Asnis GM; Miller AH
    Aliment Pharmacol Ther; 2007 May; 25(10):1163-74. PubMed ID: 17451562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F; Janssen G; Martin G; Lorenz R; Loeschke K; Soyka M; Folwaczny C; Schaefer M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1049-59. PubMed ID: 19691667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
    Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
    Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
    Laguno M; Blanch J; Murillas J; Blanco JL; León A; Lonca M; Larrousse M; Biglia A; Martinez E; García F; Miró JM; de Pablo J; Gatell JM; Mallolas J
    Antivir Ther; 2004 Dec; 9(6):905-9. PubMed ID: 15651749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z; Delić D; Marić NP; Vuković O; Jašović-Gašić M
    Psychiatr Danub; 2011 Dec; 23(4):370-7. PubMed ID: 22075738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of depression and somatic symptoms in patients on interferon alpha/ribavirin for chronic hepatitis C.
    Shakoor A; Shafqat F; Mehmud Te; Akram M; Riaz S; Iqbal Z; Khan AA
    J Ayub Med Coll Abbottabad; 2010; 22(4):6-9. PubMed ID: 22455250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
    Morasco BJ; Rifai MA; Loftis JM; Indest DW; Moles JK; Hauser P
    J Affect Disord; 2007 Nov; 103(1-3):83-90. PubMed ID: 17292481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
    Diez-Quevedo C; Masnou H; Planas R; Castellví P; Giménez D; Morillas RM; Martín-Santos R; Navinés R; Solà R; Giner P; Ardèvol M; Costa J; Diago M; Pretel J
    J Clin Psychiatry; 2011 Apr; 72(4):522-8. PubMed ID: 21034680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
    Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C
    J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.
    Honda T; Katano Y; Urano F; Murayama M; Hayashi K; Ishigami M; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Gastroenterol Hepatol; 2007 Jul; 22(7):989-95. PubMed ID: 17608843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience.
    Pojoga C; Dumitraşcu DL; Pascu O; Grigorescu M
    J Gastrointestin Liver Dis; 2006 Mar; 15(1):31-5. PubMed ID: 16680230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Depressive disturbances during antiviral therapy in patients with type C hepatitis].
    Ignatova TM; Kinkul'kina MA; Morozov AO; Avdeeva TI; Volkov AV; Tikhonova IuG
    Klin Med (Mosk); 2007; 85(7):58-63. PubMed ID: 17882814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation.
    Chapman J; Oser M; Hockemeyer J; Weitlauf J; Jones S; Cheung R
    Am J Gastroenterol; 2011 Dec; 106(12):2123-32. PubMed ID: 21826113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C.
    Amodio P; De Toni EN; Cavalletto L; Mapelli D; Bernardinello E; Del Piccolo F; Bergamelli C; Costanzo R; Bergamaschi F; Poma SZ; Chemello L; Gatta A; Perini G
    J Affect Disord; 2005 Jan; 84(1):93-8. PubMed ID: 15620390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State of the iron metabolism in patients with chronic hepatitis C type C does not influence antiviral treatment with interferon and ribavirin.
    Jurczyk K; Karpińska E; Wawrzynowicz-Syczewska M; Morańska I; Noceń I; Chlubek D; Boroń-Kaczmarska A
    Hepatogastroenterology; 2008; 55(82-83):557-61. PubMed ID: 18613407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
    da Silva TM; Munhoz RP; Alvarez C; Naliwaiko K; Kiss A; Andreatini R; Ferraz AC
    J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.